New Study Finds Clearblue(R) Easy Fertility Monitor To Significantly Increase Chances Of Conception

Main Category: Fertility
Also Included In: Medical Devices / Diagnostics
Article Date: 12 Jan 2007 - 0:00 PDT

email to a friend   printer friendly   opinions  

Accurately pinpointing the fertile period and timing intercourse accordingly are critical when trying to get pregnant. Healthy couples only have a 25% chance of conceiving each month(1) and it takes on average 6-18 months to get pregnant(2). But new research proves that one at-home fertility predictor in particular can significantly improve the odds of a quicker conception.

The study has shown that use of the Clearblue(R) Easy Fertility Monitor can dramatically increase a woman's chance of conception over two cycles of use(3). The results of this controlled study are being published in the February issue of the American Society for Reproductive Medicine's publication Fertility & Sterility. Clearblue Easy is manufactured and marketed by Inverness Medical Innovations, Inc.

Findings revealed that approximately 23% of women who took part in the research using the Monitor(3) became pregnant during the first two cycles of use, compared with 14% of the women who were not using the Monitor(3). This indicates that over a third more women conceived using the Clearblue(R) Easy Fertility Monitor. Additionally, product feedback was overwhelmingly positive with 90% of participants agreeing that the Fertility Monitor was easy to use.

The Clearblue(R) Easy Fertility Monitor is a personal computer that monitors the two key fertility hormones, Luteinizing Hormone (LH) and Estrogen (E3G), to prospectively identify six fertile days. Traditional ovulation predictors only identify two fertile days, and other conception methods (e.g. Basal Body, Salivary Ferning), monitor the effects of changing hormones and not the hormone levels themselves.

"This study offers conclusive scientific evidence that The Clearblue(R) Easy Fertility Monitor aids in the conception process by helping women accurately determine their fertile days," explains Jayne E. Ellis, Ph.D. from Inverness Medical Innovations, Inc. "And it further demonstrates that the monitor is the most advanced home method for increasing the chances of conception. The Clearblue(R) Easy Fertility Monitor can empower women who are planning a pregnancy, enabling them to understand their individual cycles."

The Clearblue(R) Easy Fertility Monitor is designed to adapt to the individual and stores up to six cycles worth of history to build a complete picture of the woman's most fertile days. In laboratory tests, the monitor is 99% accurate at detecting the LH surge, which signals ovulation. Clearblue(R) Easy is the only maker of the Fertility Monitor -- the only product and technology of its kind.

About Clearblue(R) Easy

Inverness Medical Innovations is one of the world's leading women's health consumer and professional diagnostics companies, and manufacturers and marketers of The Clearblue (R) Easy Fertility Monitor, Digital Ovulation Test and The Clearblue(R) Easy Digital Pregnancy Test. Clearblue(R) Easy is the only family planning brand to have a full digital portfolio of products -- giving women results in words and symbols -- and was the first on the market to offer digital ovulation and pregnancy tests. The Clearblue(R) Easy family of fertility and pregnancy products are 99 percent accurate in laboratory tests and are available at retail drug stores nationwide. For more information on the Clearblue(R) family of products, please visit http://www.clearblueeasy.com. For more information about Inverness Medical Innovations, visit http://www.invernessmedical.com.

(1) Infertility. Tan SL and Jacobs HS. McGraw Hill Book Co. 1991.

(2) RESOLVE.com: The National Infertility Association web site.

(3) Unipath Ltd, the manufacturers of Clearblue(R) researched the effect using the Clearblue(R) Fertility Monitor has on pregnancy rates in women trying to conceive. The research was carried out by Janet E. Robinson F.I.B.S., Melanie Wakelin, C.Stat and Jayne E. Ellis, Ph.D. The research took place in the United States.

Participants (653) were women actively trying to conceive. They were randomly assigned to either use (305), or not use (348) the Clearblue(R) Easy Fertility Monitor for two cycles to measure cumulative pregnancy rates during that period. Participants could also use other aids to conception.

Data was self-reported by volunteers using daily diaries, supplied and collected by mail. The participants were asked to record information on menstruation, intercourse, and for those in the 'using the Clearblue(R) Easy Fertility Monitor' group, the fertile days displayed by the device.

Selection criteria for participants were women who were wishing to conceive, aged 21 to 40 years, but with the maximum of 15% of total participants in the 35-40 year age group, and with a partner aged 21 to 50 years. Women were excluded if they were using hormonal birth control; fertility drugs that contained human chorionic gonadotrophin or LH; had a medical condition that presented a risk if they became pregnant, or if they had been trying to conceive for more than two years. All pregnancies were self reported and no medical data was collected to confirm pregnancy.

Clearblue(R) Easy
http://www.clearblueeasy.com

• Additional
• References
• Citations